Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

Moderna Seeks US Approval of Second Covid Booster

Moderna announced Thursday it had asked the United States drug regulator for emergency authorization for a second booster shot of the company's Covid-19 vaccine for all adults. The request to the US Food and Drug Administration (FDA) would "allow for a fourth dose of our #COVID19 vaccine in adults 18…

Asharq Al-Awsat

Moderna requests FDA approval for fourth COVID shot for adults

Moderna Inc. has filed for U.S. regulatory clearance of a second COVID-19 booster shot for all adults, covering significantly more people than Pfizer Inc. and BioNTech SE’s request earlier this week for a more limited emergency authorization for those over 65.

Tribune News Service

Moderna asks FDA to authorize additional booster shot for all adults

Moderna asks FDA to authorize additional booster shot for all adults

The request is much broader than Pfizer's, which sought to authorize a second booster for people over 65.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Vic strikes mRNA vaccine deal with Pfizer

Drug company Pfizer has agreed to increase collaboration with Victorian researchers working on mRNA vaccines.

Aurobindo gets licence for supply of Pfizer’s Covid pill

HYDERABAD: Pharma major Aurobindo Pharma Limited has inked a sub-license agreement with the United Nations-backed public health organisation Medicines Patent Pool (MPP) for manufacturing and supplying a generic version of Pfizer’s oral Covid-19 treatment drug nirmatrelvir to 95 countries, including India.

The Times of India

Anti-vaxxers are claiming an outbreak of Japanese encephalitis is really being caused by adverse reactions to Pfizer's vaccine. Here's why that's bunkum

Anti-vaxxers are once again using a Pfizer document to spread misinformation, this week claiming that Japanese encephalitis is a cover-up for adverse reactions to the company's vaccine.

19 firms in India to make Pfizer’s oral COVID-19 antiviral drug

They have signed sublicence agreements with United Nations-backed Medicines Patent Pool

inkl

Read news from The Economist, FT, and more,
with one subscription

35 Generic Drugmakers Sign To Manufacture Low-Cost Version Of Pfizer's COVID Pill

35 Generic Drugmakers Sign To Manufacture Low-Cost Version Of Pfizer's COVID Pill

Thirty-five generic drugmakers will produce low-cost versions of Pfizer Inc's (NYSE:PFE) COVID-19 pill, Paxlovid, to expand supplies of the highly effective drug in lower-income regions. Pfizer struck a deal last year with the group to allow generic drugmakers to make the pills for 95 low- and middle-income countries, covering up to approximately 53% of the…

More than 30 companies to start making Pfizer's COVID pill

More than 30 companies to start making Pfizer's COVID pill

The U.N.-backed Medicines Patent Pool says that nearly three dozen companies worldwide will soon start making generic versions of Pfizer’s coronavirus pill

The Independent UK

Health Canada Approves Moderna's COVID-19 Vaccine For Kids Aged 6-11 Years

Health Canada Approves Moderna's COVID-19 Vaccine For Kids Aged 6-11 Years

Health Canada has approved Moderna Inc's (NASDAQ:MRNA) mRNA COVID-19 vaccine, Spikevax, two-dose series of 50 µg per dose to prevent COVID-19 in children aged six to11 years. The announcement follows the recent authorization of the Company's COVID-19 vaccine in the same age group in both Australia and the European Union. "Health Canada was…

Alnylam Hits Pfizer, Moderna With Patent Infringement Suits

Alnylam Hits Pfizer, Moderna With Patent Infringement Suits

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) has filed separate lawsuits in the Delaware federal court against Pfizer Inc (NYSE:PFE) and Moderna Inc (NASDAQ:MRNA), seeking damages for infringement of a patent in the manufacture and sale of their mRNA COVID-19 vaccines. Alnylam said it was seeking compensation for the use of its lipid nanoparticles (LNP) technology that carries and delivers…

GlaxoSmithKline says it will not start any new clinical trials in Russia

GlaxoSmithKline says it will not start any new clinical trials in Russia

Pharma firm joins AstraZeneca and Pfizer in saying it will not enrol new patients into studies

The Guardian - UK

Ionis Pharma Announces Publication Of Positive Donidalorsen Data For Angioedema Attacks

Ionis Pharma Announces Publication Of Positive Donidalorsen Data For Angioedema Attacks

Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced the publication of Phase 2 data for donidalorsen in the New England Journal of Medicine (NEJM). Donidalorsen is an investigational antisense medicine under development for hereditary angioedema (HAE), a disorder characterized by recurrent episodes of severe swelling. In the Phase 2 study, donidalorsen demonstrated a 90% reduction in…

COVID boosters' short effectiveness window brings skepticism about 4th shot

COVID boosters' short effectiveness window brings skepticism about 4th shot

Some experts are already skeptical that another shot is warranted for most people.

Get all your
news in one place.

100's of premium titles.
One news app.

Los Angeles Times

Second COVID-19 booster shot does little to stop omicron, study finds

Israeli health care workers who were boosted with a fourth shot of COVID-19 vaccine at the height of the omicron wave were only marginally more protected against reinfection than their peers who had received three jabs of vaccine, researchers reported Wednesday.

What Are Whales Doing With Pfizer

A whale with a lot of money to spend has taken a noticeably bullish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 17 strange trades.

The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study

Here's a roundup of top developments in the biotech space over the last 24 hours.

Asharq Al-Awsat

Pfizer-BioNTech Seek US Approval of Second Covid Booster for 65+

Pfizer and BioNTech announced Tuesday they had formally asked the United States drug regulator for emergency approval of a second booster shot of their Covid vaccine for people aged 65 and older. The companies said in a press statement that their request is based off two Israeli studies that show…

Get all your
news in one place.

100's of premium titles.
One news app.

Tribune News Service

Pfizer asks FDA to clear another booster for older adults

Pfizer Inc. said it has asked U.S. regulators for clearance of an additional COVID-19 booster shot for seniors, in a bid to protect vulnerable adults as immunity provided by the first three doses wanes.

The Loop: Another Pfizer booster on table in US, hospital hostages in beseiged Mariupol, and a Grammys showstopper

Here's your TL;DR for this morning's news.

The Independent UK

AP source: Pfizer seeking OK for 4th COVID dose for seniors

Drugmaker Pfizer is expected to request authorization this week for an additional COVID-19 booster dose for seniors

Pfizer and BioNTech plan to seek authorization for second COVID booster for people 65 and up

The move is an attempt to bolster waning immunity that occurs several months after a first booster shot.

Tribune News Service

Fourth COVID shot will be ‘necessary,’ says Pfizer CEO

Tribune News Service

Pfizer halts trials in Russia but will continue to supply drugs

Pfizer Inc. said it would no longer start new clinical trials in Russia and that it would donate all profits from its subsidiary in the country to Ukraine relief causes.

The Independent UK

Pfizer CEO says fourth vaccine dose will be needed

CDC only authorised third jab for most adults in the fall

1 … 61 62 63 64

People

Nicolás Maduro

Tanya Plibersek

Stéphane Bancel

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Food and Drug Administration

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

355,834 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play